Last quarter (Q4 2022), Redcare Pharmacy's total revenue was €327.83M, an increase of 13.82% from the same quarter last year. In Q4, Redcare Pharmacy's net income was €-9.77M. See Redcare Pharmacy’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	€ 1.20B	-	€ 1.20B	€ 1.06B	€ 968.06M	€ 701.01M
Cost of Revenue	€ 872.57M	-	€ 872.57M	€ 793.79M	€ 748.53M	€ 563.33M
Gross Profit	€ 331.79M	-	€ 331.79M	€ 266.53M	€ 219.53M	€ 137.68M
Operating Expense	€ 401.11M	-	€ 401.11M	€ 309.94M	€ 220.46M	€ 171.86M
Operating Income	€ -69.32M	-	€ -69.32M	€ -43.41M	€ -931.00K	€ -34.18M
Net Non Operating Interest Income Expense	€ -14.03M	-	€ -14.03M	€ -13.09M	€ -14.48M	€ -10.03M
Other Income Expense	-	-	-	-	-	-
Pretax Income	€ -84.12M	-	€ -84.12M	€ -77.88M	€ -15.93M	€ -42.18M
Tax Provision	€ -6.47M	-	€ -6.47M	€ -3.70M	€ 839.00K	€ -5.91M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	€ -77.65M	-	€ -77.65M	€ -74.19M	€ -16.77M	€ -36.27M
Basic EPS	€ -3.75	-	€ -4.32	€ -4.15	€ -1.17	€ -2.78
Diluted EPS	€ -3.75	-	€ -4.32	€ -4.15	€ -1.17	€ -2.78
Basic Average Shares	€ 18.10M	-	€ 17.98M	€ 17.88M	€ 14.38M	€ 13.06M
Diluted Average Shares	€ 18.10M	-	€ 17.98M	€ 17.88M	€ 14.38M	€ 13.06M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	€ 1.27B	-	€ 1.27B	€ 1.10B	€ 968.99M	€ 735.19M
Net Income From Continuing And Discontinued Operation	€ -77.65M	-	€ -77.65M	€ -74.19M	€ -16.77M	€ -36.27M
Normalized Income	€ -77.65M	-	€ -75.00M	€ -52.81M	€ -16.52M	€ -36.79M
Interest Expense	€ 8.50M	-	€ 8.50M	€ 8.57M	€ 10.76M	€ 7.48M
EBIT	€ -75.61M	-	€ -75.61M	€ -69.32M	€ -5.17M	€ -34.70M
EBITDA	€ -36.10M	€ 50.94M	€ -36.10M	€ -42.35M	€ 10.89M	€ -19.83M

Currency in EUR

Redcare Pharmacy Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing